Invest New Drugs 2012;30(1):200-211
A small error in drawing the syringe is less impactful
The results were significant: At 48 weeks, participants receiving the 12 mg dose achieved a mean weight reduction of 24.2% (approximately 58 pounds or 26.2 kg) 100% of participants on the 8 mg or 12 mg doses lost at least 5% of their body weight More than 90% of participants on the 12 mg dose lost at least 10% of their body weight Nearly half of participants on the highest dose lost 25% or more of their body weight The study also showed improvements in cardiometabolic markers including blood pressure, triglycerides, LDL cholesterol, and fasting glucose
Current Evidence Level Stating the evidence tier precisely, without softening: Weighing the positive and negative studies The positive human evidence is real but structurally weak, and the weakness is specific: nearly all of it comes from a single investigator group
Recent filings indicate ongoing disputes over the scope of medical record production and expert retention deadlines
In contrast the findings for glutamine were inconsistent with two studies reporting no significant difference in serum glutamine in children with autistic disorder compared with controls [69, 89], a later study reporting a significant decrease in platelet glutamine in children with autistic disorder [68] and further studies that reported serum glutamate to be significantly higher in adults with autistic disorder [75] and children with autism spectrum disorders (mixed diagnoses) than controls [87]
